LISTING OF CLAIMS:

The Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 40 (previously presented): A method for treating breast cancer in a patient having a chemotherapy responsive breast cancer, comprising the steps of:

(a) administering to the patient in a first plurality of chemotherapy cycles a therapeutically-effective and well-tolerated amount of doxorubicin, said first plurality chemotherapy cycles being administered in a dose-dense protocol;

(b) after the completion of the first plurality of chemotherapy cycles, administering to the patient in a second plurality of chemotherapy cycles a therapeutically-effective and well-tolerated amount of a taxane chemotherapy agent, said second plurality of chemotherapy cycles being administered in a dose-dense protocol; and

(c) after the completion of the second plurality of chemotherapy cycles, administering to the patient in a third plurality of chemotherapy cycles a therapeutically-effective and well-tolerated amount of cyclophosphamide, said third plurality of chemotherapy cycles being administered in a dose-dense protocol.

Claim 41 (previously presented): The method of claim 40, wherein the dose-dense protocol specifies an interval of time between any two consecutive chemotherapy cycles of less than 21 days.

Claim 42 (previously presented): The method of claim 41, wherein the dose-dense protocol specifies an interval of time between any two consecutive chemotherapy cycles of between 12 and 16 days.

Claim 43 (previously presented): The method of claim 42, wherein the dose-dense protocol specifies an interval of time between any two consecutive chemotherapy cycles of about 14 days.

Claim 45 (previously presented): The method of claim 41, 42~~,~~ or 43 ~~or 44~~ wherein the number of cycles in each plurality of chemotherapy cycles is 3 or more.

Claim 46 (previously presented): The method of claim 45, wherein the number of cycles in each plurality of chemotherapy cycles is 4.

Claim 47 (previously presented): The method of claim 46, wherein the doxorubicin is administered in an amount of 60 mg/m^2.

Claim 48 (previously presented): The method of claim 47, wherein the taxane is paclitaxel.

Claim 49 (previously presented): The method of claim 48, wherein the paclitaxel is administered in an amount of 175 mg/m^2.

Claim 50 (previously presented): The method of claim 49, wherein the cyclophosphamide is administered in an amount of 600 mg/m^2.

Claim 51 (previously presented): The method of claim 40, wherein the number of cycles in each plurality of chemotherapy cycles is 3 or more.

Claim 52 (previously presented): The method of claim 51, wherein the number of cycles in each plurality of chemotherapy cycles is 4.

Claim 53 (previously presented): The method of claim 52, wherein the doxorubicin is administered in an amount of 60 mg/m^2.

Claim 54 (previously presented): The method of claim 53, wherein the taxane is paclitaxel.

Claim 55 (previously presented): The method of claim 54, wherein the paclitaxel is administered in an amount of 175 mg/m^2.

Claim 56 (previously presented): The method of claim 55, wherein the cyclophosphamide is administered in an amount of 600 mg/m^2.

Claim 57 (previously presented): The method of claim 40, wherein the doxorubicin is administered in an amount of 60mg/m^2.

Claim 58 (previously presented): The method of claim 57 wherein the taxane is paclitaxel.

Claim 59 (previously presented): The method of claim 58, wherein the paclitaxel is administered in an amount of 175 mg/m^2.

Claim 60 (previously presented): The method of claim 59, wherein the cyclophosphamide is administered in an amount of 600 mg/m^2.

Claim 61 (previously presented): The method of claim 40 wherein the taxane is paclitaxel.

Claim 62 (previously presented): The method of claim 61, wherein the paclitaxel is administered in an amount of 175 mg/m^2.

Claim 63 (previously presented): The method of claim 62, wherein the cyclophosphamide is administered in an amount of 600 mg/m^2.

Claim 64 (previously presented): The method of claim 40, wherein the cyclophosphamide is administered in an amount of 600 mg/m^2.

Claim 65 (previously presented): The method of claim 40, further comprising the step of administering to the patient a therapeutically effective amount of granulocyte colony stimulating factor (G-CSF).

Claim 66 (previously presented): The method of claim 65 wherein the G-CSF is administered between the chemotherapy cycles.

Claim 67 (previously presented): The method of claim 65 wherein the dose-dense protocol specifies an interval of time between any two consecutive chemotherapy cycles of less than 21 days.

Claim 68 (previously presented): The method of claim 67 wherein the dose-dense protocol specifies an interval of time between any two consecutive chemotherapy cycles of between 12 and 16 days.

Claim 69 (previously presented): The method of claim 68 wherein the dose-dense protocol specifies an interval of time between any two consecutive chemotherapy cycles of about 14 days.

Claim 71 (previously presented): The method of claim 67, 68~~,~~ or 69 ~~or 70~~, wherein the number of cycles in each plurality of chemotherapy cycles is 3 or more.

Claim 72 (previously presented): The method of claim 71, wherein the number of cycles in each plurality of chemotherapy cycles is 4.

Claim 73 (previously presented): The method of claim 72, wherein the doxorubicin is administered in an amount of 60 mg/m^2.

Claim 74 (previously presented): The method of claim 73, wherein the taxane is paclitaxel.

Claim 75 (previously presented): The method of claim 74, wherein the paclitaxel is administered in an amount of 175 mg/m^2.

Claim 76 (previously presented): The method of claim 75, wherein the cyclophosphamide is administered in an amount of 600 mg/m^2.

Claim 77 (previously presented): The method of claim 65 wherein the number of cycles in each plurality of chemotherapy cycles is 3 or more.

Claim 78 (previously presented): The method of claim 77, wherein the number of cycles in each plurality of chemotherapy cycles is 4.

Claim 79 (previously presented): The method of claim 78, wherein the doxorubicin is administered in an amount of 60 mg/m^2.

Claim 80 (previously presented): The method of claim 79, wherein the taxane is paclitaxel.

Claim 81 (previously presented): The method of claim 80, wherein the paclitaxel is administered in an amount of 175 mg/m^2.

Claim 82 (previously presented): The method of claim 81, wherein the cyclophosphamide is administered in an amount of 600 mg/m^2.

Claim 119 (previously presented): A method for treating breast cancer in a patient having a chemotherapy responsive breast cancer, comprising administering to the patient in a dose-dense protocol, therapeutically-effective and well-tolerated amounts of doxorubicin, a taxane and cyclophosphamide in a plurality of chemotherapy cycles, wherein the doxorubicin, taxane and cyclophosphamide are administered sequentially.

Claim 120 (previously presented): The method of claim 119, wherein the doxorubicin is administered first, the taxane second and the cyclophosphamide third.

Claim 121 (previously presented): The method of claim 119, wherein the doxorubicin is administered first, the cyclophosphamide second and the taxane third.

Claim 122 (previously presented): The method of claim 119, wherein the taxane is administered first, the doxorubicin second and the cyclophosphamide third.

Claim 123 (previously presented): The method of claim 119, wherein the taxane is administered first, the cyclophosphamide second and the doxorubicin third.

Claim 124 (previously presented): The method of claim 119, wherein the cyclophosphamide is administered first, the taxane second and the doxorubicin third.

Claim 125 (previously presented): The method of claim 119, wherein the cyclophosphamide is administered first, the doxorubicin second and the taxane third.

Claim 126 (previously presented): The method of claim 120, 121, 122, 123, 124 or 125, wherein the dose-dense protocol specifies an interval of time between any two consecutive chemotherapy cycles of less than 21 days.

Claim 127 (previously presented): The method of claim 120, 121, 122, 123, 124 or 125, wherein the dose-dense protocol specifies an interval of time between any two consecutive chemotherapy cycles of between 12 and 16 days.

Claim 128 (previously presented): The method of claim 120, 121, 122, 123, 124 or 125, wherein the dose-dense protocol specifies an interval of time between any two consecutive chemotherapy cycles of about 14 days.